Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
03 Agosto 2023 - 5:05PM
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage
oncology company developing novel targeted therapies for
RAS-addicted cancers, today announced that it will report financial
results for the second quarter 2023 on Tuesday, August 8, 2023,
after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m.
Pacific Time), Revolution Medicines’ senior management team will
host a webcast to discuss the financial results for the quarter and
provide an update on corporate progress.
To listen to the live webcast, or access the
archived webcast, please visit:
https://ir.revmed.com/events-and-presentations. Following the live
webcast, a replay will be available on the company’s website for at
least 14 days.
About Revolution Medicines,
Inc.Revolution Medicines is a clinical-stage oncology
company developing novel targeted therapies for RAS-addicted
cancers. The company’s R&D pipeline comprises RAS(ON)
Inhibitors designed to suppress diverse oncogenic variants of RAS
proteins, and RAS Companion Inhibitors for use in combination
treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236
(RASMULTI), RMC-6291(KRASG12C) and RMC-9805 (KRASG12D) are
currently in clinical development. Additional RAS(ON) Inhibitors in
the company’s pipeline include RMC-0708 (KRASQ61H) which is
currently in IND-enabling development, RMC-8839 (KRASG13C), and
additional compounds targeting other RAS variants. RAS Companion
Inhibitors in clinical development include RMC-4630 (SHP2) and
RMC-5552 (mTORC1/4EBP1).
Investors & Media Contact:
Erin Graves
650-779-0136
egraves@revmed.com
Revolution Medicines (NASDAQ:RVMD)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Revolution Medicines (NASDAQ:RVMD)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024